CCM
CLVS

Consonance Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Consonance Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-544,843
Closed -$51M – 23
2017
Q2 		$51M Sell
544,843
-789,624
-59% -$48.3M 6.01% 9
2017
Q1 		$85M Sell
1,334,467
-1,396,420
-51% -$84.9M 8.91% 4
2016
Q4 		$121M Sell
2,730,887
-800,600
-23% -$28.2M 13.32% 1
2016
Q3 		$127M Buy
3,531,487
+595,000
+20% +$12.8M 12.25% 1
2016
Q2 		$40.3M Buy
+2,936,487
New +$42.9M 5.7% 11
2015
Q4 		– Sell
-45,183
Closed -$4.16M – 28
2015
Q3 		$4.16M Sell
45,183
-257,948
-85% -$22.3M 0.58% 19
2015
Q2 		$26.6M Buy
+303,131
New +$25.9M 2.68% 12
2014
Q2 		– Sell
-200,600
Closed -$13.9M – 30
2014
Q1 		$13.9M Buy
200,600
+58,300
+41% +$4.28M 2.07% 19
2013
Q4 		$8.58M Buy
142,300
+800
+0.6% +$43.5K 1.41% 22
2013
Q3 		$8.6M Buy
141,500
+59,000
+72% +$4.18M 2.15% 17
2013
Q2 		$5.53M Buy
+82,500
New +$3.71M 1.97% 15

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Consonance Capital Management's CLVS Position: Q3 2017 in Review

Consonance Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 544,843 shares — an estimated $51M sold.

Consonance Capital Management first reported a position in CLVS in Q2 2013 and held it in 11 quarters. The position peaked at $127M in Q3 2016. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Consonance Capital Management reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Consonance Capital Management sold 544,843 Clovis Oncology, Inc. shares in Q3 2017, an estimated $51M.
  • Consonance Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 11 quarters.
  • Consonance Capital Management's Clovis Oncology, Inc. position peaked at $127M in Q3 2016.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Consonance Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.